CSIMarket
 
Vincerx Pharma Inc   (VINC)
Other Ticker:  
 
 
Price: $5.5800 $-0.41 -6.845%
Day's High: $6.3316 Week Perf: -30.77 %
Day's Low: $ 5.45 30 Day Perf: 215.25 %
Volume (M): 593 52 Wk High: $ 9.37
Volume (M$): $ 3,307 52 Wk Avg: $1.42
Open: $6.05 52 Wk Low: $0.61



 Market Capitalization (Millions $) 118
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0

Vincerx Pharma Inc
Vincerx Pharma Inc is a biopharmaceutical company focused on the development and commercialization of next-generation targeted therapies for various forms of cancer. The company's mission is to provide innovative treatment options to patients with limited or no effective treatment choices. Vincerx Pharma aims to address unmet medical needs by advancing novel drug candidates through rigorous research and development processes. The company is committed to improving patient outcomes and quality of life by leveraging its expertise in precision medicine and targeted therapeutics.


   Company Address: 260 Sheridan Avenue, Suite 400 Palo Alto 94306 CA
   Company Phone Number: 800-6676   Stock Exchange / Ticker: NASDAQ VINC
   VINC is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

A Ray of Hope: Vincerx Pharma's Enitociclib Combination Therapy Shows Promise in Lymphoma Treatment

Published Sun, Jan 7 2024 8:00 PM UTC

Vincerx Pharma's Enitociclib Shows Promise in Combating Lymphoma, According to National Institutes of Health (NIH) ReportVincerx Pharma, a leading biopharmaceutical company, recently announced the remarkable clinical efficacy of Enitociclib in combination with Venetoclax and Prednisone in lymphoma patients. The findings were reported by investigators from the prestigious Na...

Clinical Study

Revolutionary ADC Therapy VIP943 Unveiled: Vincerx Pharma Paves the Way to Precise and Safe Cancer Treatment

Published Sun, Dec 10 2023 5:00 PM UTC


Introduction
In an exciting development for the field of oncology, Vincerx Pharma Inc. presented its latest preclinical findings at the prestigious ASH 2023 conference. The company's VersAptx platform, known for its cutting-edge antibody-drug conjugate (ADC) technology, took center stage with the unveiling of the novel CD123-targeted ADC, VIP943. The poster presenta...

Vincerx Pharma Inc

Major Pharmaceutical Preparations Company Turns the Tide: Q3 2023 Earnings Season Sees Remarkable $16.9 Million Boost!

Financial News Report: Vincerx Pharma Inc Shows Improved Efficiency in Q3 2023 with Decreased Operating Deficit
In the Major Pharmaceutical Preparations sector, analysts are closely examining the third-quarter financial results of Vincerx Pharma Inc for the period between July and September 2023. While the company has not yet disclosed its top-line figures, observers have noted an operating deficit of $-10.317 million for this reporting period.
Comparing this deficit to the previous year's Q3 results, it is clear that Vincerx Pharma Inc has made significant strides in improving its financial efficiency. In the same period of 2022, the company reported an operating deficit of $-16.901 million, indicating a noteworthy reduction.

Vincerx Pharma Inc

Vincerx Pharma Inc's Q1 2023 Financials Reveal Improved Efficiency and Promising Growth Opportunities

Investors in the stock market have been watching the pharmaceutical industry closely, particularly the major players in the sector. However, there is good news for those looking to invest in smaller companies in the industry. Vincerx Pharma Inc has reported its Q1 2023 financials, and the company is showing signs of operating more efficiently than in the past.
Despite a reported operating deficit of $-15.099 million, investors can take comfort in the fact that Vincerx was able to conduct its business in a more cost-effective way than it had in the first quarter of 2022. Last year the company reported an operating deficit of $-21.627 million. This means that Vincerx has been able to trim its losses and operate in a more streamlined manner, which is a positive sign for investors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com